- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 Infection
- Interventions
- NVX-CoV2705 Vaccine
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Austin, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 34
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Influenza
- Interventions
- Quadrivalent VLP Vaccine, Comparator TIV
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- Anaheim, California • Miami, Florida • Lenexa, Kansas + 2 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSV-F Vaccine, Phosphate Buffer Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 1,330 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 10
- States / cities
- Redding, California • Stockbridge, Georgia • Lenexa, Kansas + 7 more
- Conditions
- Influenza (Pandemic)
- Interventions
- Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant, Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 610 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- Walnut Creek, California • Miami, Florida • Meridian, Idaho + 2 more
- Conditions
- Influenza
- Interventions
- Influenza VLP Vaccine, TIV
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 467 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 6
- States / cities
- Pembroke Pines, Florida • Rochester, Minnesota • Providence, Rhode Island + 3 more
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection, Upper Respiratory Disease
- Interventions
- Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
- Biological
- Lead sponsor
- Sarang K. Yoon, DO, MOH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,188 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSV-F Vaccine, Saline Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 1,599 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- Redding, California • Stockbridge, Georgia • Lenexa, Kansas + 7 more
- Conditions
- COVID-19
- Interventions
- NVX-CoV2373 (5μg), NVX-CoV2601(5μg), NVX-CoV2601(35μg), NVX-CoV2601(50μg), Bivalent BA.4/5
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 994 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Banning, California + 44 more
- Conditions
- COVID-19, SARS-CoV-2 Infection
- Interventions
- NVX-CoV2705
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years to 90 Years
- Enrollment
- 676 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Melrose Park, Illinois • Lenexa, Kansas + 7 more
- Conditions
- COVID-19, Sars-CoV-2 Infection
- Interventions
- NVX-CoV2705, Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 50 Years to 65 Years
- Enrollment
- 6,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 99
- States / cities
- Athens, Alabama • Birmingham, Alabama • Gadsden, Alabama + 88 more
- Conditions
- Influenza
- Interventions
- NanoFlu, Fluzone HD - Day 0, Fluzone HD - Day 21, Saline - Day 21
- Biological · Other
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Raleigh, North Carolina • Rocky Mount, North Carolina • Statesville, North Carolina
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Low dose RSV F Antigen, High dose RSV F Antigen, Dose 1 of Aluminum Adjuvant, Dose 2 of Aluminum Adjuvant, Dose 3 of Aluminum Adjuvant, Dose 4 of Aluminum Adjuvant, Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 720 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 10
- States / cities
- Walnut Creek, California • Stockbridge, Georgia • Boise, Idaho + 7 more
- Conditions
- Influenza (Pandemic)
- Interventions
- Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant, Saline placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 333 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Anaheim, California • Miami, Florida • Pembroke Pines, Florida + 2 more
- Conditions
- Influenza
- Interventions
- Influenza VLP Vaccine (recombinant), Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 317 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Pembroke Pines, Florida • Kansas City, Missouri • Warwick, Rhode Island + 1 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28), High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Melbourne, Florida • Dallas, Texas + 1 more
- Conditions
- COVID-19
- Interventions
- XBB.1.5 Vaccine (Booster), XBB.1.5 Vaccine (single dose)
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 30
- States / cities
- Mobile, Alabama • Sacramento, California • Colorado Springs, Colorado + 26 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV F vaccine with adjuvant, Formulation buffer
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 4,636 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Fort Defiance, Arizona + 43 more
- Conditions
- Pandemic Influenza
- Interventions
- H5N1 VLP Vaccine, Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Low dose RSV-F Vaccine with Adjuvant, Low dose RSV-F Vaccine without Adjuvant, High dose RSV-F Vaccine with Adjuvant, High dose RSV-F Vaccine without Adjuvant, Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing], Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 330 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 4
- States / cities
- Anaheim, California • Rockville, Maryland • Mt. Pleasant, South Carolina + 1 more
- Conditions
- COVID-19
- Interventions
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo
- Biological · Other
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 6 Months to 11 Years
- Enrollment
- 3,600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 47
- States / cities
- Little Rock, Arkansas • Anaheim, California • Bellflower, California + 41 more
- Conditions
- SARS-CoV Infection, Covid19
- Interventions
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), Placebo (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)
- Biological · Other
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 33,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 144
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 110 more
- Conditions
- Influenza (Pandemic)
- Interventions
- Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant, Saline Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 333 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Anaheim, California • Miami, Florida • Pembroke Pines, Florida + 2 more
- Conditions
- COVID-19
- Interventions
- NVX-CoV2373, SARS-CoV-2 rS antigen/Matrix-M Adjuvant
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 5
- States / cities
- Austin, Texas • Fort Worth, Texas • Plano, Texas + 1 more
- Conditions
- COVID-19, SARS-CoV-2 Infection
- Interventions
- NVX-Cov2373
- Drug
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 911 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 30
- States / cities
- Long Beach, California • Sacramento, California • DeLand, Florida + 26 more